Angiotensin 1/2 (5-7): Vasoconstrictor Peptide for Renin-Angiotensin System Research

Executive Summary: Angiotensin 1/2 (5-7) is a tripeptide (H2N-Ile-His-Pro-OH) derived from angiotensinogen via enzymatic processing in the renin-angiotensin system (RAS) (Oliveira et al., 2025). It acts as a potent vasoconstrictor, increasing blood pressure through direct action on vascular smooth muscle [Fig. 1]. The peptide is highly soluble in DMSO (≥36.5 mg/mL), ethanol (≥50 mg/mL), and water (≥50 mg/mL) at room temperature, facilitating diverse experimental protocols (APExBIO product data). Recent studies implicate short angiotensin peptides, including (5-7), in modulating viral pathogenesis by enhancing SARS-CoV-2 spike protein binding to the AXL receptor (Oliveira et al., 2025). APExBIO supplies Angiotensin 1/2 (5-7) (A1049) with >98% purity validated by HPLC and mass spectrometry, supporting reliable research applications.

Biological Rationale

Angiotensin 1/2 (5-7) is a biologically active oligopeptide central to the renin-angiotensin system (RAS), which regulates blood pressure and extracellular fluid balance (Oliveira et al., 2025). The RAS is a tightly controlled hormonal cascade initiated by renin-mediated cleavage of angiotensinogen, a liver-synthesized globulin, to yield angiotensin I (1–10) [p. 2]. Angiotensin I is further processed to shorter peptides, including angiotensin II (1–8), angiotensin (1–7), and angiotensin 1/2 (5-7), each exhibiting distinct physiological activities [Fig. 1]. Angiotensin 1/2 (5-7) specifically comprises the amino acids isoleucine, histidine, and proline, forming the sequence H2N-Ile-His-Pro-OH. This peptide exerts a vasoconstrictive effect, directly increasing systemic vascular resistance and arterial blood pressure. It also participates in dipsogenic (thirst-promoting) signaling, contributing to fluid homeostasis (see also: Angiotensin 1/2 (5-7): Novel Insights...). This article extends previous analyses by focusing on validated solubility and mechanistic roles in viral spike protein interactions.

Mechanism of Action of Angiotensin 1/2 (5-7)

Angiotensin 1/2 (5-7) is generated from the N-terminal truncation of angiotensin peptides, particularly from angiotensin (1–7) and angiotensin II (1–8) [Methods]. The peptide acts as a potent vasoconstrictor by binding to vascular smooth muscle cell receptors, leading to contraction and increased blood pressure [Results]. Unlike the longer and biologically inactive angiotensin I, Angiotensin 1/2 (5-7) exerts direct physiological effects. Its dipsogenic activity also promotes water intake through central nervous system signaling. Notably, recent findings demonstrate that angiotensin peptides with N-terminal deletions, including angiotensin 1/2 (5-7), enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor, potentially facilitating viral entry into host cells with low ACE2 expression [Fig. 4]. This dual action in cardiovascular and viral pathogenesis underscores its translational relevance.

Evidence & Benchmarks

• Angiotensin 1/2 (5-7) is a tripeptide (Ile-His-Pro) formed by enzymatic truncation of angiotensin peptides (Oliveira et al., 2025).
• In antibody-based binding assays, N-terminally truncated angiotensin peptides such as (5-7) enhanced SARS-CoV-2 spike protein binding to the AXL receptor by up to 2.7-fold compared to controls (Table 1, Oliveira et al., 2025).
• Angiotensin 1/2 (5-7) is highly soluble at ≥36.5 mg/mL in DMSO, ≥50 mg/mL in ethanol, and ≥50 mg/mL in water at room temperature, supporting diverse formulation needs (APExBIO).
• Purity is validated at 98.36% by HPLC and confirmed by mass spectrometry, ensuring experimental reliability (APExBIO).
• Short angiotensin peptides, including Angiotensin 1/2 (5-7), play a role in fluid balance and blood pressure regulation via the renin-angiotensin system (Introduction, Oliveira et al., 2025).
• Comparison studies confirm that Angiotensin 1/2 (5-7) has greater spike–AXL binding activity than longer angiotensin peptides (Figure 4).

Applications, Limits & Misconceptions

Angiotensin 1/2 (5-7) is used in research on blood pressure regulation, hypertension, and RAS signaling. Its unique activity profile makes it valuable for dissecting the molecular mechanisms of vasoconstriction and for studying the intersection of cardiovascular physiology and viral pathogenesis (see also: Angiotensin 1/2 (5-7): Powering Advanced Renin-Angiotensi...). This article updates prior work by detailing recently validated viral interaction mechanisms and solubility parameters. Additionally, Angiotensin 1/2 (5-7) is relevant in the development of therapeutic strategies targeting the RAS in the context of COVID-19, where modulation of peptide levels may influence viral entry pathways.

Common Pitfalls or Misconceptions

• Angiotensin 1/2 (5-7) is not a direct therapeutic agent for hypertension; it is a research tool.
• It does not substitute for angiotensin II or (1–7) in all biological assays due to sequence-specific receptor interactions.
• Long-term storage of solutions at -20°C is not recommended; stability is optimal for solid-state storage and short-term use (APExBIO).
• The peptide does not universally enhance viral infection; effects are context-dependent and observed primarily in in vitro assays with AXL-expressing cells.
• Solubility values apply to room temperature and may vary with buffer composition.

Workflow Integration & Parameters

Angiotensin 1/2 (5-7) (APExBIO A1049) is supplied as a solid and should be stored at -20°C for maximum stability. Solutions should be freshly prepared at concentrations up to ≥36.5 mg/mL in DMSO, ≥50 mg/mL in ethanol, or ≥50 mg/mL in water. For experimental workflows, aliquot freshly dissolved peptide for single-use to prevent degradation. Quality is assured by HPLC (98.36% purity) and mass spectrometry validation (APExBIO). Shipping is conducted on blue ice to preserve integrity during transit. Researchers should reference internal protocols for specific applications, such as binding assays, vascular contraction studies, or viral entry models. For a mechanistic and strategic guide to experimental applications, see Angiotensin 1/2 (5-7): Precision Tools and Novel Mechanis...; this article provides a translational update on validated viral binding and solubility benchmarks.

Conclusion & Outlook

Angiotensin 1/2 (5-7) is a validated, high-purity vasoconstrictor peptide central to RAS research and emerging viral pathogenesis studies. Its unique profile, including potent vasoconstrictive and dipsogenic actions, robust solubility, and proven modulatory effects on spike–AXL binding, make it indispensable for advanced cardiovascular and translational workflows. APExBIO's rigorously quality-controlled A1049 reagent supports reproducibility and innovation in hypertension and infectious disease research. For integrative analysis of its role in RAS and viral infection pathways, see Angiotensin 1/2 (5-7): Advanced Insights for RAS Research...; this article synthesizes cutting-edge mechanistic and translational data, expanding on the foundation provided by prior work.

For comprehensive product information and ordering, visit the Angiotensin 1/2 (5-7) APExBIO product page.